SETD5 in glioma cells conferred TRAIL resistance induction
8.0
来源：
Nature
关键字：
ML brain science
发布时间：
2025-09-30 07:43
摘要：
SETD5 is identified as a key player in glioblastoma (GBM) resistance to TRAIL-induced apoptosis. The study reveals that SETD5 is significantly overexpressed in GBM, particularly in aggressive subtypes, and its knockdown enhances the efficacy of TRAIL treatment by promoting apoptotic pathways. This research highlights SETD5's potential as a therapeutic target to improve treatment outcomes for GBM patients, suggesting that targeting SETD5 may overcome TRAIL resistance and enhance therapeutic efficacy.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分+1.0分
business_impact
0.5分+0.5分
scientific_rigor
1.5分+1.5分
timeliness_innovation
1.5分+1.5分
investment_perspective
2.5分+2.5分
market_value_relevance
1.0分+1.0分
team_institution_background
0.5分+0.5分
technical_barrier_competition
1.0分+1.0分
关键证据
SETD5 is significantly upregulated in GBM compared to normal brain tissues.
Knockdown of SETD5 enhances TRAIL-mediated apoptosis.
SETD5 expression correlates with immune evasion and poor prognosis in GBM.
真实性检查
否
AI评分总结
SETD5 is identified as a key player in glioblastoma (GBM) resistance to TRAIL-induced apoptosis. The study reveals that SETD5 is significantly overexpressed in GBM, particularly in aggressive subtypes, and its knockdown enhances the efficacy of TRAIL treatment by promoting apoptotic pathways. This research highlights SETD5's potential as a therapeutic target to improve treatment outcomes for GBM patients, suggesting that targeting SETD5 may overcome TRAIL resistance and enhance therapeutic efficacy.